References
1. D'Amico, F., F. Gomollón, G. Bamias, et al., Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study. United European Gastroenterol J, 2024.
2. Vega, P., J.M. Huguet, E. Gómez, et al., IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management. Dig Dis Sci, 2024.
3. Turner, D., A. Ricciuto, A. Lewis, et al., STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021. 160(5): p. 1570-1583.
4. Zammarchi, I., G. Santacroce, and M. Iacucci, Next-Generation Endoscopy in Inflammatory Bowel Disease. Diagnostics, 2023. 13(15): p. 2547.
5. Vestergaard, M.V., K.H. Allin, G.J. Poulsen, et al., Characterizing the pre-clinical phase of inflammatory bowel disease. Cell Rep Med, 2023. 4(11): p. 101263.
6. Rodríguez-Lago, I., J. Blackwell, B. Mateos, et al., Recent Advances and Potential Multi-Omics Approaches in the Early Phases of Inflammatory Bowel Disease. J Clin Med, 2023. 12(10).
7. Strohl, M., L. Gonczi, Z. Kurt, et al., Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol, 2018. 24(22): p. 2363-2372. DOI: 10.3748/wjg.v24.i22.2363
8. Noor, N.M., J.C. Lee, S. Bond, et al., A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol, 2024. DOI: 10.1016/S2468-1253(24)00034-7
9. Geem, D., D. Hercules, R.S. Pelia, et al., Progression of Pediatric Crohn's Disease Is Associated With Anti-Tumor Necrosis Factor Timing and Body Mass Index Z-Score Normalization. Clin Gastroenterol Hepatol, 2024. 22(2): p. 368-376.e4.
10. Jongsma, M.M.E., L.M.M. Costes, I. Tindemans, et al., Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments. J Crohns Colitis, 2023. 17(8): p. 1262-1277.
11. Danese, S., S. Vermeire, G. D'Haens, et al., Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol, 2022. 7(4): p. 294-306.
12. Correction to Lancet Gastroenterol Hepatol 2022; 7: 294-306. Lancet Gastroenterol Hepatol, 2022. 7(4): p. e8.
13. Colombel, J.F., G. D'Haens, W.J. Lee, et al., Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis, 2020. 14(2): p. 254-266.
14. Colombel, J.F., R. Panaccione, P. Bossuyt, et al., Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, 2017. 390(10114): p. 2779-2789.
15. Danese, S., E. Schabel, J. Masure, et al., Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. J Crohns Colitis, 2016. 10 Suppl 2: p. S548-52.
16. Krugliak Cleveland, N., J. St-Pierre, A. Kellar, et al., Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. Curr Gastroenterol Rep, 2024. 26(2): p. 31-40.
17. Siffledeen, J., S. Singh, S.M. Shulman, et al., Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD-PODCAST Canada Trial. Dig Dis Sci, 2024. 69(5): p. 1636-1648.
18. Barreiro-de Acosta, M., A. Gutiérrez, Y. Zabana, et al., Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. United European Gastroenterol J, 2021. 9(7): p. 766-772.
19. Fiorino, G., T. Lytras, L. Younge, et al., Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. J Crohns Colitis, 2020. 14(8): p. 1037-1048.
20. Limketkai, B.N., S. Singh, V. Jairath, et al., US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis, 2019. 25(11): p. 1828-1837.
21. Wagatsuma, K., Y. Yokoyama, and H. Nakase, Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel), 2021. 11(12).
22. Buisson, A., F. Gonzalez, F. Poullenot, et al., Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis, 2017. 23(8): p. 1425-1433.
23. Dignass, A., F. D'Amico, F. Gomollón, et al., P808 Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results. Journal of Crohn's and Colitis, 2024. 18(Supplement_1): p. i1504-i1505.
24. Maréchal, C., I. Aimone-Gastin, C. Baumann, et al., Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United European Gastroenterol J, 2017. 5(5): p. 702-707.
25. Wetwittayakhlang, P., P.A. Golovics, A.A. Khoury, et al., Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. J Gastrointestin Liver Dis, 2022. 31(4): p. 403-410.
26. Neurath, M.F., Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol, 2017. 14(5): p. 269-278.
27. Palmela, C., J. Torres, and M. Cravo, New Trends in Inflammatory Bowel Disease. GE - Portuguese Journal of Gastroenterology, 2015. 22(3): p. 103-111.